Mary Wilson
Well-known member
Volume 41, Issue 29, 29 June 2023, Pages 4206-4211
https://doi.org/10.1016/j.vaccine.2023.06.013
Woo Joo Kim [SUP]a[/SUP], Christine C. Roberts [SUP]b[/SUP], Joon Young Song [SUP]a[/SUP], Jin Gu Yoon [SUP]a[/SUP], Hye Seong [SUP]a[/SUP], Hak-Jun Hyun [SUP]a[/SUP], Hyojin Lee [SUP]b[/SUP], Areum Gil [SUP]b[/SUP], Yeeun Oh [SUP]b[/SUP], Ji-Eun Park [SUP]b[/SUP], Ji-Eun Lee [SUP]b[/SUP], Bohyun Jeon [SUP]b[/SUP], Deborah Kane [SUP]b[/SUP], Susan Spruill [SUP]c[/SUP], Sagar B. Kudchodkar [SUP]b[/SUP], Kar Muthumani [SUP]b[/SUP], Young K. Park [SUP]b[/SUP], Ijoo Kwon [SUP]b[/SUP], Joel N. Maslow [SUP]b[/SUP] [SUP]d[/SUP]
Abstract
Heterologous boost regimens are being increasingly considered against SARS-CoV-2. We report results for the 32 of 45 participants in the Phase 1 CoV2-001 clinical trial (Kim et al., Int J Iinfect Dis 2023, 128:112–120) who elected to receive an EUA-approved SARS-CoV-2 mRNA vaccine 6 to 8 months following a two-dose primary vaccination with the GLS-5310 bi-cistronic DNA vaccine given intradermally and followed by application of suction using the GeneDerm device. Receipt of EUA-approved mRNA vaccines after GLS-5310 vaccination was well-tolerated, with no reported adverse events. Immune responses were enhanced such that binding antibody titers, neutralizing antibody titers, and T-cell responses increased 1,187-fold, 110-fold, and 2.9-fold, respectively. This paper is the first description of the immune responses following heterologous vaccination with a DNA primary series and mRNA boost.
https://doi.org/10.1016/j.vaccine.2023.06.013
Woo Joo Kim [SUP]a[/SUP], Christine C. Roberts [SUP]b[/SUP], Joon Young Song [SUP]a[/SUP], Jin Gu Yoon [SUP]a[/SUP], Hye Seong [SUP]a[/SUP], Hak-Jun Hyun [SUP]a[/SUP], Hyojin Lee [SUP]b[/SUP], Areum Gil [SUP]b[/SUP], Yeeun Oh [SUP]b[/SUP], Ji-Eun Park [SUP]b[/SUP], Ji-Eun Lee [SUP]b[/SUP], Bohyun Jeon [SUP]b[/SUP], Deborah Kane [SUP]b[/SUP], Susan Spruill [SUP]c[/SUP], Sagar B. Kudchodkar [SUP]b[/SUP], Kar Muthumani [SUP]b[/SUP], Young K. Park [SUP]b[/SUP], Ijoo Kwon [SUP]b[/SUP], Joel N. Maslow [SUP]b[/SUP] [SUP]d[/SUP]
Abstract
Heterologous boost regimens are being increasingly considered against SARS-CoV-2. We report results for the 32 of 45 participants in the Phase 1 CoV2-001 clinical trial (Kim et al., Int J Iinfect Dis 2023, 128:112–120) who elected to receive an EUA-approved SARS-CoV-2 mRNA vaccine 6 to 8 months following a two-dose primary vaccination with the GLS-5310 bi-cistronic DNA vaccine given intradermally and followed by application of suction using the GeneDerm device. Receipt of EUA-approved mRNA vaccines after GLS-5310 vaccination was well-tolerated, with no reported adverse events. Immune responses were enhanced such that binding antibody titers, neutralizing antibody titers, and T-cell responses increased 1,187-fold, 110-fold, and 2.9-fold, respectively. This paper is the first description of the immune responses following heterologous vaccination with a DNA primary series and mRNA boost.